NCT05290662 - Registry of Patients Having Received oNKord® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

AML

Interventions

DRUG

oNKord®

Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells

DRUG

Cyclophosphamide/Fludarabine (Cy/Flu)

Lymphodepleting conditioning regimen

Trial Locations (2)

RECRUITING

Medizinische Hochschule Hannover, Hanover

RECRUITING

University Hospital Basel, Basel